Serina Therapeutics Statistics Share Statistics Serina Therapeutics has 9.97M
shares outstanding. The number of shares has increased by 12.23%
in one year.
Shares Outstanding 9.97M Shares Change (YoY) 12.23% Shares Change (QoQ) 0.35% Owned by Institutions (%) 3.44% Shares Floating 3.27M Failed to Deliver (FTD) Shares 6,647 FTD / Avg. Volume 31.03%
Short Selling Information The latest short interest is 38.77K, so 0.39% of the outstanding
shares have been sold short.
Short Interest 38.77K Short % of Shares Out 0.39% Short % of Float 0.67% Short Ratio (days to cover) 1.25
Valuation Ratios The PE ratio is -3.31 and the forward
PE ratio is -3.31.
Serina Therapeutics's PEG ratio is
0.01.
PE Ratio -3.31 Forward PE -3.31 PS Ratio 658.37 Forward PS 832 PB Ratio 57.52 P/FCF Ratio -2.15 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Serina Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.4,
with a Debt / Equity ratio of 0.42.
Current Ratio 2.4 Quick Ratio 2.4 Debt / Equity 0.42 Debt / EBITDA -0.03 Debt / FCF -0.02 Interest Coverage -32.41
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $4.67K Profits Per Employee $-928.42K Employee Count 12 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -20.4% in the
last 52 weeks. The beta is 0.67, so Serina Therapeutics's
price volatility has been higher than the market average.
Beta 0.67 52-Week Price Change -20.4% 50-Day Moving Average 5.69 200-Day Moving Average 5.34 Relative Strength Index (RSI) 50.23 Average Volume (20 Days) 21,420
Income Statement In the last 12 months, Serina Therapeutics had revenue of 56K
and earned -11.14M
in profits. Earnings per share was -1.51.
Revenue 56K Gross Profit -138K Operating Income -17.05M Net Income -11.14M EBITDA -10.49M EBIT -10.68M Earnings Per Share (EPS) -1.51
Full Income Statement Balance Sheet The company has 3.67M in cash and 268K in
debt, giving a net cash position of 3.4M.
Cash & Cash Equivalents 3.67M Total Debt 268K Net Cash 3.4M Retained Earnings -44.32M Total Assets 6.73M Working Capital 3.4M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -17.14M
and capital expenditures -22K, giving a free cash flow of -17.16M.
Operating Cash Flow -17.14M Capital Expenditures -22K Free Cash Flow -17.16M FCF Per Share -2.33
Full Cash Flow Statement Margins Gross margin is -246.43%, with operating and profit margins of -30442.86% and -19894.64%.
Gross Margin -246.43% Operating Margin -30442.86% Pretax Margin -20012.5% Profit Margin -19894.64% EBITDA Margin -18726.79% EBIT Margin -30442.86% FCF Margin -30641.07%
Dividends & Yields SER does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SER is $13,
which is 154.4% higher than the current price. The consensus rating is "Buy".
Price Target $13 Price Target Difference 154.4% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 15, 2024. It was a
backward
split with a ratio of 7:250.
Last Split Date Mar 15, 2024 Split Type backward Split Ratio 7:250
Scores Altman Z-Score -3.59 Piotroski F-Score 3
